In patients with AML bearing an NPM1 mutation, an IDH1/2 mutation, an FLT3‐ITD mutation, an FLT3‐TKD mutation, a NUP98 rearrangement, or a TP53 mutation, the CR rate after one cycle was 94.4% (17/18), 90.9% (20/22), 89.5% (17/19), 87.5% (7/8), 75.0% (3/4), and 0% (0/1), respectively (Table S4, Supporting Information). This evidence concerns the gene TP53 and acute myeloid leukemia.